Table 2.
Summary of hESC, hiPSC or multipotent cell transplantation trials in the world for retinal disease therapy from 2010 to 2022
| Disease | Phase | Identifier | Transplanted cells | Transplant | Location | Patient number | Immunosuppression | Sponsor | Study start |
|---|---|---|---|---|---|---|---|---|---|
| RP | I | NCT01068561* | BMSCs | Cell suspension (autologous) | IV | 5 | University of Sao Paulo | 2010 | |
| I | NCT01531348e | MSCs | Cell suspension (autologous) | IV | 10 | Mahidol University | 2012 | ||
| II | NCT01560715* | BMSCs | Cell suspension | IV | 50 | University of Sao Paulo | 2012 | ||
| I | NCT01736059r | CD34+ cells | Cell suspension (autologous) | IV | 15 | University of California Davis | 2012 | ||
| I | NCT02280135* | BMSCs | Cell suspension (autologous) | IV | 8 | Red de Terapia Celular | 2014 | ||
| I/II | NCT01914913u | BMSCs | Cell suspension (autologous) | 15 | Chaitanya Hospital, Pune | 2014 | |||
| I/II | NCT02464436r | hRPCs | Cell suspension | SR | 29 | Unknown | ReNeuron Limited | 2015 | |
| I/II | NCT02320812* | hRPCs | Cell suspension (allogenic) | IV | 28 | jCyte, Inc. | 2015 | ||
| II | NCT03073733* | RPCs | Cell suspension | IV | 84 | Unknown | jCyte, Inc. | 2017 | |
| I | NCT03772938u | BMSCs | Cell suspension (autologous) | IV | 30 | Pomeranian Medical University Szczecin | 2018 | ||
| I/II | NCT03963154r | hESC-RPE cells | – | SR | 12 | Unknown | Centre d’Etude des Cellules Souches | 2019 | |
| I | NCT04925687r | CD34+ cells | Cell suspension | IV | 4 | Unknown | University of California | 2021 | |
| AMD | I/II | NCT01344993* | hESC-RPE cells | Cell suspension | SR | 13 | Tacrolimus/mycophenolate mofetil | Astellas Institute for Regenerative Medicine | 2011 |
| I/II | NCT01518127* | BMSCs | Cell suspension (autologous) | IV | 20 | University of Sao Paulo | 2011 | ||
| I/II | NCT01674829u | hESC-RPE cells | Cell suspension | SR | 12 | Tacrolimus/mycophenolate mofetil | CHABiotech Co. | 2012 | |
| I | NCT01736059r | CD34+ celss | Cell suspension (autologous) | IV | 15 | University of California Davis | 2012 | ||
| I/II | NCT02463344og | hESC-RPE cells | Cell suspension | SR | 11 | Tacrolimus/mycophenolate mofetil | Astellas Institute for Regenerative Medicine | 2013 | |
| I/II | NCT02016508u | BMSCs | Cell suspension (autologous) | IV | 1 | Al-Azhar University | 2013 | ||
| UMIN000011929* | hiPSC-RPE cells | Cell suspension (autologous) | 2 | RIKEN | 2013 | ||||
| I/II | NCT02286089og | hESC-RPE cells | Cell suspension | SR | 24 | Unknown | Lineage Cell Therapeutics | 2015 | |
| I/II | NCT02749734u | hESC-RPE cells | Cell suspension | SR | 15 | Tacrolimus/mycophenolate mofetil/predisone | Southwest Hospital | 2015 | |
| II | NCT02563782w | hESC-RPE cells | Cell suspension | SR | 0 | Tacrolimus/mycophenolate mofetil | Astellas Institute for Regenerative Medicine | 2015 | |
| I/II | NCT02903576* | hESC-RPE cells | Patch/Cell suspension | SR | 15 | Unknown | Federal University of Sao Paulo | 2015 | |
| I | NCT01691261og | hESC-RPE cells | Patch | 2 | Fluocinolone/prednisolone | Pfizer/University College London | 2015 | ||
| – | ChiCTR-OCB-15007054* | hESC-RPE cells | SR | 10 | Unknown | Chinese Academy of Sciences | 2015 | ||
| I/II | NCT02590692og | hESC-RPE cells | Patch-CPCB | SR | 16 | Unknown | Regenerative Patch Technologies, Inc. | 2016 | |
| I | NCT03102138og | hESC-RPE cells | Patch | 2 | Unknown | Moorfields Eye Hospital NHS Foundation Trust | 2017 | ||
| I/II | NCT03178149og | hESC-ASP7317 | Cell suspension | 18 | Tacrolimus | Astellas Institute for Regenerative Medicine | 2017 | ||
| I/II | NCT03046407r | hESC-RPE cells | Cell suspension | SR | 10 | Unknown | Chinese Academy of Sciences | 2017 | |
| I/II | NCT02755428r | hESC-RPE cells | Cell suspension | SR | 10 | Unknown | Chinese Academy of Sciences | 2018 | |
| I/II | NCT03167203e | hESC-RPE cells | Cell suspension | SR | 36 | Unknown | Astellas Institute for Regenerative Medicine | 2018 | |
| I | NCT03772938u | BMSCs | Cell suspension (autologous) | IV | 30 | Pomeranian Medical University | 2018 | ||
| I/II | NCT04339764r | hiPSC-RPE cells | RPE-PLGA (autologous) | SR | 20 | National Eye Institute | 2020 | ||
| STGD1 | I/II | NCT01345006* | hESC-RPE cells | Cell suspension | SR | 13 | Tacrolimus/mycophenolate mofetil | Astellas Institute for Regenerative Medicine | 2011 |
| I/II | NCT01469832* | hESC-RPE cells | Cell suspension | SR | 12 | Tacrolimus/mycophenolate mofetil | Astellas Institute for Regenerative Medicine | 2011 | |
| I/II | NCT01518127* | BMSCs | Cell suspension (autologous) | IV | 20 | University of Sao Paulo | 2011 | ||
| I/II | NCT02445612og | hESC-RPE cells | Cell suspension | SR | 13 | Tacrolimus/mycophenolate mofetil | Astellas Institute for Regenerative Medicine | 2012 | |
| I | NCT01625559u | hESC-RPE cells | Cell suspension | SR | 3 | Tacrolimus/mycophenolate mofetil | CHABiotech Co. | 2012 | |
| I/II | NCT02941991* | hESC-RPE cells | Cell suspension | SR | 12 | Unknown | Astellas Institute for Regenerative Medicine | 2013 | |
| I/II | NCT02749734u | hESC-RPE cells | Cell suspension | SR | 15 | Tacrolimus/mycophenolate mofetil/predisone | Southwest Hospital | 2015 | |
| I/II | NCT02903576* | hESC-RPE cells | Patch/Cell suspension | SR | 15 | Unknown | Federal University of Sao Paulo | 2015 | |
| I | NCT03772938u | BMSCs | Cell suspension (autologous) | IV | 30 | Pomeranian Medical University | 2018 |
Clinical trials: Completed*, enrolling by invitatione, ongoingog, recruitingr, status unknownu, withdrawnw. AMD: Age-related macular degeneration; BMSC: bone marrow stem cell; CPCB: mesh-supported submicron parylene C membrane; hESC: human embryonic stem cell; hiPSC: human induced pluripotent stem cell; hRPC: human retinal progenitor cell; IV: intravitreal; MSC: mesenchymal stem cell; PR: photoreceptor; RP: retinitis pigmentosa; RPE: retinal pigment epithelial cell; SR: subretinal; STGD1: Stargardt macular degeneration.